Brief: Savara Announces The U.K. Medicines And Healthcare Products Regulatory Agency (Mhra) Has Accepted The Molbreevi* Marketing Authorisation Application (Maa) For Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)
07/04/2026 13:08
April 7 (Reuters) - Savara Inc SVRA.O: SAVARA ANNOUNCES THE U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) HAS ACCEPTED THE MOLBREEVI* MARKETING AUTHORISATION APPLICATION (MAA) FOR AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) SAVARA INC - MHRA DECISION ON MOLBREEVI MAA EXPECTED IN Q4 2026 SAVARA INC - FDA PDUFA DATE FOR MOLBREEVI BLA SET FOR AUGUST 22, 2026 SAVARA INC - CHMP DECISION ON MOLBREEVI MAA EXPECTED IN Q1 2027 Source text: ID:nBw5WV8Gma Further company coverage: SVRA.O ((Reuters.Briefs@thomsonreuters.com;))